Clinical trial NCT01318902 - References

Light-Chain Amyloidosis — Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Citation(s)

•   Merlini G, Sanchorawala V, Zonder J, Kukreti V, Schonland S, Jaccard A, et al
  MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a phase 1 study. In: 54th ASH Annu
•   Sanchorawala V, Comenzo R, Zonder J, Kukreti V, Cohen A, Dispenzieri A, et al
  MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed or refractory lightchain (AL) amyloidosis. Clinical Lymphoma Myeloma and Leukemia 2013;13(suppl 1):S153-
•   Sanchorawala V, Zonder J, Comenzo R, Schönland S, Dispenzieri A, Berg D, et al
  Poster Presentation: Phase 1 study of MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis. XIII Intern

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment

Details for clinical trial NCT01318902